🎥@GABOUALFA (@MSKCancerCenter) highlights exciting anti-TIGIT therapies for hepatocellular carcinoma. Promising results from MORPHEUS-Liver trial with tiragolumab, atezolizumab, and bevacizumab: ➡️https://t.co/hR1dCQJTBi⬅️ #ASCO23 #Oncology #ImmunoOnc (@VJOncology)

Is anyone studying SBRT + IO? Encouraged by the recent success of SBRT + atezo in early stage NSCLC- but not sure if the same biological rationale is present here (maybe in later line or high TMB NETs) @RachelRiechelm2 (@JohnEbbenMDPhD)

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in HCC @OncologyAdvance https://t.co/xit1v39BjF ❓What should we do and what can we expect for 2nd line therapy 🌍RWD suggest: 👉AtzeBev > Lenva 👉Lenva > ICI @myESMO @ILCAnews @EASLedu… https://t.co/ALX315Novm (@ArndtVogel)

🚨Very high PD-L1 expression (>90%), high TMB, and increased CD8+PD1+ T cells density associate w/ prolonged benefit from CRT ➡️durvalumab in stage III #NSCLC. Out in @NatureComms our multi-center analysis led by🌟 @alessi_joao. #biomarkers can help⬆️outcomes. @OncoAlert #LCSM (@BiagioRicciutMD)

Impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC – @alessi_joao #MemorialSloanKetteringCancer #cancer #danafarber #durvalumab #pneumonitis #oncology #oncodaily https://t.co/CQD3cZyn5m (@oncodaily)

Cabozantinib in combination with atezolizumab in non-clear cell #RCC: Extended follow-up results of cohort 10 of the #COSMIC021 study. @BradMcG04 @DanaFarber joins @PBarataMD @caseccc to discuss these results on UroToday > https://t.co/RBIepZ1r4w @ExelixisInc (@urotoday)

CONTACT-3 clearly shows the addition of atezolizumab to cabozantinib is no better than cabo alone in advanced renal cancer patients who have had PD on PD1 therapy. It seems to add to toxicity with no subset benefiting. (@tompowles1)

Treatment with atezolizumab plus cabozantinib after initial disease progression on a prior frontline ICI–based regimen did not produce superior survival benefit for patients with advanced RCC. @DrChoueiri @DanaFarber @harvardmed @ASCO #ASCO23 #kcsm https://t.co/SkHNjc3tBf (@OncLive)

Resection for multifocal HCC? Only the exceptional case. It will be interesting to see how adjuvant atezo/bev changes practice. Of note, 90% of patients enrolled in the trial had a solitary HCC. https://t.co/C8mZkmJ5Rs. (@DenboJw)

#Italian real-world evidence of #durvalumab, gemcitabine, cisplatin in advanced #biliarytractcancer #cholangiocarcinoma #CCA #BTC ⁦@LiverInt⁩ ⁦@casadei_gardini⁩ ⁦@lonardi_sara⁩ ⁦@Mom_enji⁩ ⁦@HUNIMED⁩ ⁦@HumanitasMilano⁩ https://t.co/ENsCg2QXMK (@LorenzaRimassa)

Our last paper—> Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data @LorenzaRimassa @sara_lonardi1 @Mom_enji @fedenichetti https://t.co/5aHbvCT7Bd (@casadei_gardini)

Hearing the newest and greatest on #smallcelllungcancer from @teekayowo — atezo-chemo success in front line but much ongoing for refractory disease including ADCs targeting DLL3 & B7-H3, bispecifics, and novel radioligands! #Pitt23 @UPMC @UPMCHillmanCC (@TiansterZhang)

Check out Dr. Benjamin Besse @BenjaminBesseMD @GustaveRoussy discussing #ASCO23 LATIFY -Ceralasertib + Durvalumab vs. Docetaxel in pts w/ Locally Advanced or Met. #NSCLC That Progressed on or After Anti-PD-(L)1 & Platinum-Based Tx #LCSM #lungcancer @EORTC https://t.co/7lk52kCdH5 (@Sameh_VuMedi)

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://t.co/4dphxuN1s4 cc: @BladderCancerUS @JCensits @PGrivasMDPhD (@eaonc)

Dr. @ReneeSaliby from @DanaFarber_GU presented data on circulating and intratumoral immune determinants of response to Atezo-Beva in patients with variant histology or sarcomatoid RCC. #KCRS23 @OncoAlert (@FabioSchutz78)

Groundbreaking talk by @ReneeSaliby ⭐️ on circulating and intratumoral determinants to Atezo-Bev in non clear cell RCC #RMS #KCRS23 (@KarlSemaan)

BIOMARKERS IN RCC SYMPOSIUM 🩸 Circulating and Intratumor Immune Determinants of Response to Atezo/Bev in Patients with Variant Histology RCC @ReneeSaliby @DrChoueiri @BradMcG04 @SylvanBacaLab @BraunMDPhD @DanaFarber_GU (@MikeSerzanMD)

The addition of first-line maintenance avelumab to best supportive care has sustained tolerability in patients with advanced urothelial carcinoma. @OncoBellmunt @DanaFarber @ASCO #ASCO23 #blcsm https://t.co/DSDWFWcuCq (@OncLive)

14/15 #TumorBoardTuesday 💥New💥ways of assessing high risk localized disease? 🔍Increasing sensitive ctDNA assays allow detection of molecular residual disease (MRD) after surgery 🔎+MRD = high risk of recurrence. ✨ASPRIA phase 2 of SG + atezolizumab in pts with TNBC and +MRD (@ArielleMedford)

12/15 #TumorBoardTuesday #BCSM 📌Other ADCs target Trop2 ✨BEGONIA✨ DatoDXd + durvalumab in 29 pts w/mTNBC ➡️74% response - 7% complete, 67% partial 📚#PeterSchmid https://t.co/hLYGlnh4CT (@ArielleMedford)

@DanengLi, MD, discussed current approaches to treating biliary tract cancers, including the TOPAZ-1 study regimen of cisplatin, gemcitabine, and durvalumab. What are your thoughts on this case? #gicsm | @cityofhope https://t.co/ibhA0HJtfT https://t.co/L860Tf97dX (@TargetedOnc)

IMvigor11 in resected bladder cancer being a prognostic and predictive marker for adjuvant atezolizumab @tompowles1 (@Eduardrssl)

Long-term post hoc safety findings from JAVELIN Bladder 100 show that first-line maintenance avelumab plus best supportive care continued to be safe and tolerable in patients with urothelial carcinoma. @OncoBellmunt @DanaFarber @ASCO #ASCO23 #blcsm https://t.co/nPTQfpdnaO (@OncLive)

Fianlimab + cemiplimab produced high & consistent tumor responses in pts with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study. @OmidHamidMD @angelesclinic #melsm https://t.co/2HkK8iLO79 (@OncLive)

Atezolizumab + cabozantinib did not improve PFS or OS vs cabozantinib alone in pts w. advanced RCC who previously received treatment w/ an immune checkpoint inhibitor, missing the primary end points of the CONTACT-03 trial. @DrChoueiri @DanaFarber #kcsm https://t.co/84TwhWJhhE (@OncLive)

You can “consider” it but you can’t actually give single agent Tecentriq to a lung cancer patient in first line, insurance won’t cover it (@shycollie)

Promising immunotherapy for ‘difficult to treat’ lung cancer patients https://t.co/bLOCbb7JxW phase III trial of first-line immunotherapy treatment with atezolizumab in an advanced NSCLC population deemed unfit for standard platinum-chemotherapy @FriedbergEric @DrIanWeissman (@Nigelj08223326)

🟢New IPSOS study of @peters_solange & co in @TheLancet comparing atezolizumab 🩺🫁💉immunotherapy to chemotherapy for #lungcancer patients ineligible for platinum-based chemo. Better overall survival and fewer side effects 🔗https://t.co/E6wd1HRSjL @CHUVLausanne #Immunotherapy (@OncoUNILCHUV)

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://t.co/4dphxuN1s4 cc: @BladderCancerUS @JCensits @PGrivasMDPhD (@eaonc)

"Avelumab as first-line maintenance therapy in advanced urothelial carcinoma shows sustained tolerability and long-term benefits, according to JAVELIN Bladder 100 trial data." @OncoBellmunt @DanaFarber @ASCO #ASCO23 @oncoalert #CancerTreatment #UrothelialCarcinoma (@DrYukselUrun)

WATCH: @BrunaPellini, of @MoffittNews, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced NSCLC treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel. #oncology https://t.co/xLqMUTcDto (@OncLive)

Post-Hoc Analysis Confirms Safety of Maintenance Avelumab in Urothelial Carcinoma @OncoBellmunt @DanaFarber @ASCO #ASCO23 #blcsm https://t.co/kCqpHOY60P (@OncLive)

Excellent presentation from @BrunaPellini that demonstrates the utility of ctDNA to inform maintenance outcomes in NSCLC treated with induction atezo+chemo. #DAVAHawaiiLung https://t.co/hUy8jlJwKP (@KE_Gallaway)

📢 Exciting results from CONTACT-03 trial on atezolizumab/cabozantinib combo in advanced RCC: @DrChoueiri @DanaFarber_GU @OncoAlert #ASCO2023 1️⃣No improvement in PFS or OS compared to cabozantinib alone 2️⃣Median PFS: combo 10.6 months, cabozantinib 10.8 months 3️⃣Median OS: combo… https://t.co/C0NfmESQE9 (@nataliagandur)

Fianlimab + cemiplimab produced high & consistent tumor responses in pts with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study. @OmidHamidMD @angelesclinic #melsm https://t.co/k9EuuARjGj (@OncLive)

Atezolizumab + cabozantinib did not improve PFS or OS vs cabozantinib alone in pts w. advanced RCC who previously received treatment w/ an immune checkpoint inhibitor, missing the primary end points of the CONTACT-03 trial. @DrChoueiri @DanaFarber #kcsm https://t.co/B3u6qps1by (@OncLive)

EA8192, led by @JCensits and @PGrivasMDPhD, is a phase II/III #clinicaltrial of durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. For more: https://t.co/4dphxuN1s4 #blcsm (@eaonc)

4-yr OS update from the phs 3 HIMALAYA trial of tremelimumab + durvalumab in HCC at #WCGIC2023 👉Excellent long-term survival data for STRIDE 👉4-yr OS rate of 19% (unprecedented in HCC) 👉Long-term OS observed in relevant subgroups, incl. pts with non-viral liver disease… https://t.co/ZTzq8PM6je (@ArndtVogel)

4-years OS update from HIMALAYA ph-3 trial in unresectable hepatocellular carcinoma. STRIDE regimen (Tremelimumab + Durvalumab) maintains significant long-term OS benefit vs sorafenib. At 4 years, 1/4 of the patients in the STRIDE arm remained alive. Very good results! #WCGIC2023 (@carlosbon78)

Sugemalimab plus chemo vs placebo plus chemo in 1st line treatment of advanced esophageal carcinoma: ⬆️PFS (HR 0.57), ⬆️OS (HR 0.79) and ⬆️ORR (60.1% vs 45.2%). In subgroup analysis benefit was restricted to IHC PD-L1 CPS ≥ 10 #WCGIC2023 (@carlosbon78)

Long-term results of the #IMvigor130 study: atezolizumab with or without chemotherapy in metastatic #UrothelialCancer. @MattGalsky @TischCancer sits with @UroCancerMD @VUMCurology in this discussion on UroToday > https://t.co/y7FFr4wGUe (@urotoday)

At #ASCO23, @koshkin85 met with @tompowles1 to discuss the Q-TWiST analysis that was conducted on the JAVELIN Bladder 100 study for the estimated net benefit of avelumab plus best supportive care for patients with advanced urothelial carcinoma. Watch now: https://t.co/aIk94P7UQc (@GUOncologyNow)